Excretion of clofazimine in human milk in leprosy patients

Leprosy Review

Volumn 68, Issue 3, 1997, Pages 242-246

  Venkatesan, K ^a   Mathur, A ^a   Girdhar, A ^a   Girdhar, B K ^a  

^a NATIONAL JALMA INSTITUTE FOR LEPROSY AND OTHER MYCOBACTERIAL DISEASES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFAZIMINE; DAPSONE; LEPROSTATIC AGENT; RIFAMPICIN;

ADULT; ARTICLE; BLOOD SAMPLING; BREAST FEEDING; BREAST MILK; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG MILK LEVEL; FEMALE; HIGH PERFORMANCE THIN LAYER CHROMATOGRAPHY; HUMAN; LACTATION; LEPROSY; ORAL DRUG ADMINISTRATION; SAFETY; TIME;

EID: 0030668541     PISSN: 03057518     EISSN: None     Source Type: Journal    
DOI: 10.5935/0305-7518.19970033     Document Type: Article

References (18)

1. WHO Study Group. Chemotherapy for Leprosy Control Programmes. Technical Report Series No. 675, WHO: Geneva, 1982.
2. Aquas JT. Treatment of leprosy with lamprene (B 663 Geigy). Int. J. Lepr. 1971; 39: 493-503.
3. Venkatesan K. Clinical Pharmacokinetic considerations in the treatment of patients with leprosy. Clin. Pharmacokinet. 1989; 16: 365-386.
4. Lanyi Z, Dieterie W, Dubois JP, Theobald W, Vischer W. Pharmacokinetics of clofazimine in healthy volunteers. Int. J. Lepr. 1987; 55: 9-15.
5. Waters MMF. G 30 320 or B 663, Lamprene (Geigy); a working parry held in London in September 1968. Lepr. Rev 1969; 40: 21-47.
6. Schulz EJ. Forty four months' experience in the treatment of leprosy with Clofazimine (Lamprene-Geigy). Lepr. Rev 1971; 42: 178-187.
7. Vischer WA. The experimental properties of G 30 320 (B663) - A new anti-leprotic agent. Lepr. Rev. 1969; 40: 107-110.
8. Freerksen E, Seydel JK. Critical comments on the treatment of leprosy and other mycobacterial infections with clofazimine. Arzneimittel forschung (Drug Res.) 1992; 42: 1243-1245.
9. Lanyi Z, Dubois JP. Determination of clofazimine in human plasma by thin layer Chromatography. J. Chromatogr. 1982; 232: 219-223.
10. Peters JH, Hamme KJ, Gordon GR. Determination of clofazimine in plasma by high performance liquid chromatography. J. Chromatogr. 1982; 229: 503-508.
11. Atkinson HC, Begg EJ. Prediction of Drug distribution into human milk from physicochemical characteristics. Clin. Pharmacokinet. 1990; 18: 151-167.
12. Banerjee DK, Ellard GA, Gammon PT, Waters MFR. Some observations on the pharmacology of clofazimine (B663). Am. J. Trop. Med. Hyg. 1974; 23: 1110-1115.
13. Balakrishnan S, Desikan KV, Ramu G. Quantitative estimation of clofazimine in tissues. Lepr. India 1976; 40: (Suppl. 4): 732-738.
14. Conalty ML, Jackson RD. Uptake by reticuloendothelial cells of riminophenazine B 663. Br. J. Exptl. Pathol. 1962; 43: 650-654.
15. Levy L. Pharmacological studies of clofazimine. Am. J., Trop. Med Hyg. 1974; 23: 1097-1109.
16. Feng PCC, Fenselau CC, Jacobson RR. Metabolism of clofazimine in leprosy patients. Drug Met. Disposition 1981; 9: 521-524.
17. Sanders SW, Zone JJ, Poltz RI, Tolman KG, Rollins DE. Haemolytic anaemia induced by dapsone transmitted through breast milk. Annals Int. Med. 1982; 96: 465-466.
18. Rasmussen F. Studies in the mammary excretion and absorption of drugs, Mortensen, Copenhagen, 1966.